BR112019001206A2 - anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) - Google Patents

anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)

Info

Publication number
BR112019001206A2
BR112019001206A2 BR112019001206A BR112019001206A BR112019001206A2 BR 112019001206 A2 BR112019001206 A2 BR 112019001206A2 BR 112019001206 A BR112019001206 A BR 112019001206A BR 112019001206 A BR112019001206 A BR 112019001206A BR 112019001206 A2 BR112019001206 A2 BR 112019001206A2
Authority
BR
Brazil
Prior art keywords
hptp
ptp
monoclonal antibodies
humanized monoclonal
antibodies targeting
Prior art date
Application number
BR112019001206A
Other languages
English (en)
Inventor
Peters Kevin
Allen Flynn Michael
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of BR112019001206A2 publication Critical patent/BR112019001206A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a revelação proporciona composições e métodos para o tratamento de condições oculares associadas a angiogênese compreendendo a administração de um anticorpo que visa um inibidor da tirosina fosfatase num indivíduo.
BR112019001206A 2016-07-20 2017-07-19 anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) BR112019001206A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364381P 2016-07-20 2016-07-20
US201662377072P 2016-08-19 2016-08-19
PCT/US2017/042855 WO2018017714A1 (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Publications (1)

Publication Number Publication Date
BR112019001206A2 true BR112019001206A2 (pt) 2019-06-25

Family

ID=60988231

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001206A BR112019001206A2 (pt) 2016-07-20 2017-07-19 anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)

Country Status (13)

Country Link
US (6) US10253094B2 (pt)
EP (1) EP3487518A4 (pt)
JP (3) JP7107914B2 (pt)
KR (1) KR20190031246A (pt)
CN (1) CN109715189A (pt)
AU (1) AU2017299581A1 (pt)
BR (1) BR112019001206A2 (pt)
CA (1) CA3030298A1 (pt)
IL (1) IL263936A (pt)
MX (1) MX2019000727A (pt)
PH (1) PH12019500145A1 (pt)
SG (2) SG10201912556VA (pt)
WO (1) WO2018017714A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
US8999325B2 (en) * 2011-10-13 2015-04-07 Aerpio Therapeutics, Inc Treatment of ocular disease
BR112018075032A2 (pt) 2016-06-15 2019-03-26 Icahn School Of Medicine At Mount Sinai proteínas de hemaglutinina do vírus influenza e seus uso
CN109715189A (zh) 2016-07-20 2019-05-03 爱尔皮奥治疗有限公司 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
CN113164597A (zh) * 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3890778A4 (en) * 2018-12-03 2022-08-03 Agensys, Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME
WO2020219719A1 (en) * 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
GB2589400A (en) 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
JP2002540165A (ja) 1999-03-26 2002-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｉｅ２レセプターアクチベーターによる血管透過性の調節
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
JP2003535910A (ja) 2000-06-23 2003-12-02 シエーリング アクチエンゲゼルシャフト ＶＥＧＦ／ＶＥＧＦ及びアンギオポイエチン／Ｔｉｅ受容体機能を妨げる組合せ及び組成物、並びにそれらの使用（ＩＩ）
CN1318093C (zh) 2001-09-28 2007-05-30 参天制药株式会社 含与聚乙二醇结合的药物的眼组织注射剂
US20050260132A1 (en) 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
WO2003047611A2 (en) 2001-12-04 2003-06-12 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Ptp10d, tec and edtp involved in triglycerid-metabolism
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
AU2003243190A1 (en) 2002-05-03 2003-11-17 Regeneron Pharmaceuticals, Inc. Methods of inducing formation of functional and organized lymphatic vessels
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
AU2005327973A1 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007041317A2 (en) 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
BRPI0619853A2 (pt) 2005-12-15 2016-08-23 Astrazeneca Ab combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
CA2622312A1 (en) 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
US8044178B2 (en) * 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US7973142B2 (en) * 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009154026A1 (ja) * 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
BRPI1006898A2 (pt) 2009-01-12 2015-09-08 Akebia Therapeutics Inc métodos de tratamento da síndrome do extravasamento vascular.
WO2010097800A1 (en) 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
CN102428103B (zh) * 2009-03-24 2015-04-08 泰华生物制药美国公司 抗light的人源化抗体及其使用
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
MX354143B (es) 2009-12-02 2018-02-14 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
NZ610230A (en) 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2012109673A1 (en) 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US8999325B2 (en) * 2011-10-13 2015-04-07 Aerpio Therapeutics, Inc Treatment of ocular disease
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
MA37794B1 (fr) 2012-07-13 2017-07-31 Roche Glycart Ag Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
EP2967066B1 (en) 2013-03-15 2019-10-23 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3010526A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating macular edema
US20160137717A1 (en) 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
BR112016000177A2 (pt) 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
KR20160030504A (ko) 2013-07-11 2016-03-18 노파르티스 아게 미숙아 망막병증의 치료에 있어서 vegf 길항제의 용도
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
CA2926853C (en) 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
KR102446386B1 (ko) * 2014-01-10 2022-09-22 아납티스바이오, 아이엔씨. 인터루킨-33 (il-33)에 대한 항체
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
EP3194448A4 (en) 2014-09-16 2018-03-14 Ovascience, Inc. Anti-vasa antibodies, and methods of production and use thereof
WO2016049183A1 (en) 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
MY179505A (en) 2015-04-02 2020-11-09 Molecular Partners Ag Recombinant binding proteins and their use
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
CN116987187A (zh) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
CA2998673C (en) 2015-09-23 2023-12-12 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
EP3432927A4 (en) 2016-03-24 2019-11-20 Gensun Biopharma Inc. TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
CN109715189A (zh) 2016-07-20 2019-05-03 爱尔皮奥治疗有限公司 靶向VE-PTP(HPTP-β)的人源化单克隆抗体

Also Published As

Publication number Publication date
EP3487518A4 (en) 2020-08-12
US20200270342A1 (en) 2020-08-27
US11136389B2 (en) 2021-10-05
SG10201912556VA (en) 2020-02-27
PH12019500145A1 (en) 2019-07-29
US20180022804A1 (en) 2018-01-25
IL263936A (en) 2019-01-31
US10597452B2 (en) 2020-03-24
JP2020180156A (ja) 2020-11-05
US11180551B2 (en) 2021-11-23
CN109715189A (zh) 2019-05-03
EP3487518A1 (en) 2019-05-29
US10253094B2 (en) 2019-04-09
JP2022101694A (ja) 2022-07-06
MX2019000727A (es) 2019-05-02
WO2018017714A1 (en) 2018-01-25
US20190077862A1 (en) 2019-03-14
JP2019531259A (ja) 2019-10-31
SG11201900464TA (en) 2019-02-27
AU2017299581A1 (en) 2019-01-17
CA3030298A1 (en) 2018-01-25
US20200239567A1 (en) 2020-07-30
US20190077863A1 (en) 2019-03-14
KR20190031246A (ko) 2019-03-25
US10604569B2 (en) 2020-03-31
US20230134885A1 (en) 2023-05-04
JP7107914B2 (ja) 2022-07-27

Similar Documents

Publication Publication Date Title
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
CO2017013356A2 (es) Anticuerpos de factor xi
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
CO2017010618A2 (es) Anticuerpos contra icos
BR112016014952A2 (pt) Inibição direcionada de tgfbeta
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
BR112017022838A2 (pt) receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos
CR20190105A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
BR112016014731A2 (pt) Anticorpos anti-baff
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
EP4234013A3 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
EA201992027A1 (ru) Водный состав антитела против pd-l1
BR112017002433A2 (pt) anticorpos anticeramida
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]